Lele Liu1,2, Xingguo Song3, Xinyi Li1,2, Linlin Xue2, Shanshan Ding2,4, Limin Niu1,2, Li Xie2, Xianrang Song5. 1. School of Medicine and Life Sciences, University of Jinan, Shandong Academy of Medical Sciences, Jinan, China. 2. Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China. 3. Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China. 4. Department of Clinical Laboratory, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China. 5. Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China. basiclab@163.com.
Abstract
BACKGROUND: During the development of tumors, tumors "educate" platelets causing changes in their mRNAs expression profiles and phenotypes, thereby, tumor-educated platelet (TEP) mRNA profile has the potential to diagnose lung cancer. The current study aimed to examine whether TEPs might be a potential biomarker for lung cancer diagnostics. METHODS: Platelet precipitation was obtained by low-speed centrifugation and subjected to Trizol for total RNA extraction. Platelet MAX, MTURN, and HLA-B mRNA were selected by microarray, validated by qPCR, and analyzed combined with related clinical factors. RESULTS: Our results showed that a three-platelet mRNA set: MAX, MTURN, and HLA-B was significantly up-regulated in lung cancer patients as well as in early-stage lung cancer patients compared with those from healthy donors, the area under the curve (AUC) was 0.734, 0.787, respectively, among which platelet MTURN mRNA processed a dramatically high diagnostic efficiency in female patients with lung cancer, its AUC for female was 0.825. More importantly, the three-platelet mRNA set: MAX, MTURN, and HLA-B was associated with chemotherapeutic effect, low mRNA expression of this three-platelet set was correlated with "favorable" first chemotherapy response. CONCLUSIONS: A three-platelet mRNA set: MAX, MTURN and HLA-B enables blood-based lung cancer diagnosis and chemotherapy response prediction.
BACKGROUND: During the development of tumors, tumors "educate" platelets causing changes in their mRNAs expression profiles and phenotypes, thereby, tumor-educated platelet (TEP) mRNA profile has the potential to diagnose lung cancer. The current study aimed to examine whether TEPs might be a potential biomarker for lung cancer diagnostics. METHODS: Platelet precipitation was obtained by low-speed centrifugation and subjected to Trizol for total RNA extraction. Platelet MAX, MTURN, and HLA-B mRNA were selected by microarray, validated by qPCR, and analyzed combined with related clinical factors. RESULTS: Our results showed that a three-platelet mRNA set: MAX, MTURN, and HLA-B was significantly up-regulated in lung cancerpatients as well as in early-stage lung cancerpatients compared with those from healthy donors, the area under the curve (AUC) was 0.734, 0.787, respectively, among which platelet MTURN mRNA processed a dramatically high diagnostic efficiency in female patients with lung cancer, its AUC for female was 0.825. More importantly, the three-platelet mRNA set: MAX, MTURN, and HLA-B was associated with chemotherapeutic effect, low mRNA expression of this three-platelet set was correlated with "favorable" first chemotherapy response. CONCLUSIONS: A three-platelet mRNA set: MAX, MTURN and HLA-B enables blood-based lung cancer diagnosis and chemotherapy response prediction.
Authors: Toru Sasaki; Eugene C Gan; Andrew Wakeham; Sally Kornbluth; Tak W Mak; Hitoshi Okada Journal: Genes Dev Date: 2007-04-01 Impact factor: 11.361
Authors: Richard S Finn; Carmelo Bengala; Nuhad Ibrahim; Henri Roché; Joseph Sparano; Lewis C Strauss; Justin Fairchild; Oumar Sy; Lori J Goldstein Journal: Clin Cancer Res Date: 2011-10-25 Impact factor: 12.531
Authors: Myron G Best; Nik Sol; Sjors G J G In 't Veld; Adrienne Vancura; Mirte Muller; Anna-Larissa N Niemeijer; Aniko V Fejes; Lee-Ann Tjon Kon Fat; Anna E Huis In 't Veld; Cyra Leurs; Tessa Y Le Large; Laura L Meijer; Irsan E Kooi; François Rustenburg; Pepijn Schellen; Heleen Verschueren; Edward Post; Laurine E Wedekind; Jillian Bracht; Michelle Esenkbrink; Leon Wils; Francesca Favaro; Jilian D Schoonhoven; Jihane Tannous; Hanne Meijers-Heijboer; Geert Kazemier; Elisa Giovannetti; Jaap C Reijneveld; Sander Idema; Joep Killestein; Michal Heger; Saskia C de Jager; Rolf T Urbanus; Imo E Hoefer; Gerard Pasterkamp; Christine Mannhalter; Jose Gomez-Arroyo; Harm-Jan Bogaard; David P Noske; W Peter Vandertop; Daan van den Broek; Bauke Ylstra; R Jonas A Nilsson; Pieter Wesseling; Niki Karachaliou; Rafael Rosell; Elizabeth Lee-Lewandrowski; Kent B Lewandrowski; Bakhos A Tannous; Adrianus J de Langen; Egbert F Smit; Michel M van den Heuvel; Thomas Wurdinger Journal: Cancer Cell Date: 2017-08-14 Impact factor: 31.743